Chemical Namealpelisib
Dosage FormTablet (oral; 50 mg, 150 mg, 200 mg)
Drug ClassKinase inhibitors
SystemFemale reproductive
Approval Year2019


  • Indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen
Last updated on 3/31/2022

More on this drug: Clinical Trials

Document TitleYearSource
Piqray (alpelisib) Prescribing Information.2019Novartis Pharmaceuticals Corporation, East Hanover, NJ

Have we missed a study, or would you like to comment on a study?